The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
Abstract
Summary: Background : Infliximab treatment is effective in 70–80% of patients with refractory luminal and fistulizing Crohn's disease. The effect of infliximab is ascribed to induction of apoptosis. Aim : To study whether polymorphisms in apoptosis genes predict the response to infliximab and whether they interact with clinical predictors. Methods : Cohort of 287 consecutive patients treated with infliximab for refractory luminal (n = 204) or fistulizing (n = 83) Crohn's disease was genotyped for 21 polymorphisms in apoptosis genes. Short‐term clinical response was assessed at week 4 (luminal Crohn's disease) or 10 (fistulizing Crohn's disease) after the first infliximab infusion. Results : The response rate was 69% in luminal and 80% in fistulizing Crohn's disease. In luminal Crohn's disease, two genetic predictors were identified: (i) patients with the Fas ligand −843 CC/CT genotype (n = 135) responded in 75%, with the TT genotype (n = 21) in 38% only (P = 0.002; OR = 0.11; 95% CI: 0.08–0.56). (ii) Patients with the caspase‐9 93 TT (n = 9) genotype all responded, in contrast with 67% (n = 147) with the CC and CT genotype (P = 0.04; OR = 1.50; 95% CI: 1.34–1.68). Concomitant azathioprine/mercaptopurine therapy overcame the effect of unfavourable genotypes. In the fistulizing Crohn's disease cohort, the same Fas ligand −843 CC/CT genotype was the only predictor of response (P = 0.002; OR = 1.66; 95% CI: 1.21–2.29), interacting with caspase‐9 93 polymorphism but not with azathioprine/mercaptopurine. Conclusion : We observed that polymorphisms in FasL/Fas system and caspase‐9 influence the response to infliximab in luminal and fistulizing Crohn's disease. The strongest association was seen between the Fas ligand −843 TT genotype and non‐response. Concomitant mercaptopurine/azathioprine therapy, however, was able to overcome the effect of unfavourable genotypes in luminal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationTiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H. A., Wirtz, S., Becker, C., Atreya, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16432 · Cited by 828
Cited by
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Ding, N. S., Hart, A., & De Cruz, P. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13445 · Cited by 309
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Gisbert, J. P., & Chaparro, M. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz195 · Cited by 281
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Metadata
- Authors
- HLAVATY, T., PIERIK, M., HENCKAERTS, L., FERRANTE, M., JOOSSENS, S., VAN SCHUERBEEK, N., NOMAN, M., RUTGEERTS, P., & VERMEIRE, S.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-09-23
- Volume
- 22
- Issue
- 7
- Pages
- 613-626
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2100757339
- Cited by
- 196
- References
- 3
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.2005.02635.x
- The paper
- HLAVATY, T., PIERIK, M., HENCKAERTS, L., FERRANTE, M., JOOSSENS, S., VAN SCHUERBEEK, N., NOMAN, M., RUTGEERTS, P., & VERMEIRE, S. (2005). Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2005.02635.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.